CSL strikes $2B deal with Alentis for rare disease treatment
by@Reuters
Summary
On October 5, 2026, Australia's CSL announced a significant partnership with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first-in-class treatment for rare kidney and liver diseases, in a deal valued at up to $1.6 billion. CSL will make an upfront payment of $355 million while Alentis can earn up to $1.2 billion in future milestone payments. The drug is currently undergoing a Phase 2 trial for a rare autoimmune kidney disease and received orphan drug designation from the US Food and Drug Administration in 2024 to support its development. Upon commercialization, CSL will receive 55% of the global profits from lixudebart, whereas Alentis will receive the remaining 45%.
Tokens
$CSL$AXJO
Analysis
CSL: CSL is an Australian biotechnology company specializing in the development and commercialization of therapies for rare and serious diseases. In this development, CSL has formed a partnership with Alentis Therapeutics to co-develop and co-promote lixudebart for rare kidney and liver conditions under a co-commercialization agreement. Kyle Rodda: Kyle Rodda is a senior financial market analyst at Capital.com. He provided market commentary on the CSL-Alentis partnership, characterizing the announcement as favorable for near-term prospects while noting limited impact on the company's broader long-term outlook. Alentis Therapeutics: Alentis Therapeutics is a Swiss biopharmaceutical company focused on treatments for fibrotic and rare diseases. The firm is collaborating with CSL on the joint development and global promotion of its candidate lixudebart, formerly known as ALE.F02, which is advancing in clinical studies. Profit Allocation: Under the partnership terms, global profits from the drug will be divided with a majority share allocated to CSL upon commercialization. Regulatory Support: The US Food and Drug Administration has granted orphan drug designation to encourage development of treatments for rare diseases such as the autoimmune kidney condition targeted by lixudebart.
Categories
macro